Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sight Sciences Inc (NQ: SGHT )

3.800 -0.060 (-1.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sight Sciences Inc

< Previous 1 2 3 4 5 6 Next >
Sight Sciences' Q4 Earnings, FY22 Guidance Beat Street View
Sight Sciences Inc (NASDAQ: SGHT) has treated the first patient in the TRIDENT trial evaluating OMNI Surgical System compared to Glaukos Corp's (NYSE... 
Via Benzinga
Earnings Scheduled For March 24, 2022
Companies Reporting Before The Bell • iHuman (NYSE:IH) is likely to report earnings for its fourth quarter. • Pioneer Muni High Inc (NYSE:MAV) is expected to... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022
Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago... 
Via Benzinga
FDA Approves Sight Sciences' TearCare System For Common Eye Condition
The FDA has cleared Sight Sciences Inc's (NASDAQ: SGHT) TearCare System for meibomian gland dysfunction (MGD), the leading cause of dry eye disease (DED).... 
Via Benzinga
40 Stocks Moving In Monday's Mid-Day Session
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares climbed 83.4% to $91.52. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction.... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's morning trading, 400 companies set new 52-week lows. 52-Week Low Highlights: Intuitive Surgical (NASDAQ:ISRG) was the largest company by... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022
Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE: 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Before 10 am on Wednesday, 99 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: Sea (NYSE:SE) was the largest firm by market cap to set a... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-... 
Via Benzinga
Sight Sciences, Inc. (SGHT) Q3 2021 Earnings Call Transcript
SGHT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &... 
Via Benzinga
FDA Clears Sight Sciences' Trial Of Canaloplasty Combined With Cataract Surgery To Lower Ocular Pressure
The FDA has signed off Sight Sciences Inc's (NASDAQ: SGHT) clinical study to assess investigational higher volume OMNI device to perform canal viscodilation... 
Via Benzinga
Exposures Product Safety
Last Week's Notable Insider Buys: Navitas Semiconductor, Truist Financial And More
Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain or near highs. The initial public offering of a SPAC merger prompted... 
Via Benzinga
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021
Upgrades DA Davidson upgraded the previous rating for AAON Inc (NASDAQ: 
Via Benzinga
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
34 Stocks Moving In Tuesday's Mid-Day Session
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) shares climbed 50.9% to $4.2550. NeuroMetrix, Inc. (NASDAQ: NURO) gained 37.4% to $4.4750 as the company said it received FDA... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
Via Benzinga
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (... 
Via Benzinga
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
Stocks That Hit 52-Week Highs On Monday
This morning 121 companies reached new 52-week highs. Areas of Significance: Alphabet (NASDAQ:GOOGL) was the largest company by market cap to set a new 52-week high... 
Via Benzinga
Stocks That Hit 52-Week Highs On Friday
On Friday morning, 126 companies achieved new highs for the year. Significant Points: Microsoft (NASDAQ:MSFT) was the largest firm on a market cap basis to set a... 
Via Benzinga
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (... 
Via Benzinga
62 Biggest Movers From Yesterday
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares surged 208% to settle at $10.04 on Tuesday as the company said it received FDA breakthrough device designation for the treatment... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.